Curis Goes Above 'Erivedge' With $30M, Licensing Deal
Pulling down a $30 million loan against Erivedge royalties and spending $9.5 million to license a Phase II-ready apoptosis promoter from Genentech Inc. its partner for the skin cancer product gives Curis Inc. more financial runway, as well as worldwide rights to another promising oncology candidate.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST